Non-sedating acrivastine product
US6077537A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 21, 1998 |
| Grant date | Jun 20, 2000 |
| Priority date | — |
| Expiry date | May 21, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4439
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of using and compositions containing acrivastine which provide antihistaminic therapeutic benefits while minimizing undesirable central nervous system side effects. According to the present invention, the plasma concentration-response curve for acrivastine's sedative side effects is steeper than that of the plasma concentration-response curve for its antihistamine activity. Accordingly, when the peak blood plasma level of acrivastine is maintained within the levels provided by the present invention composition, the central nervous side effects are minimized while the antihistaminic effects are optimized.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.